Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
HKSE: 1349.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Da Jun Zhao
- Employees
- 921
- Headquarters
- Shanghai, China
- IPO year
- 2002
- Market cap
- HK$952.0M
- Website
- https://www.fd-zj.com
Loading 1349…
Loading profile data…Frequently asked questions about 1349
What does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) do?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinic...
Where does 1349.HK trade?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) trades on the Hong Kong Stock Exchange.
What sector is 1349.HK in?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.?
Da Jun Zhao is the chief executive officer of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK).
Where is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. headquartered?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is headquartered in China.
Does 1349.HK pay a dividend?
Yes — Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) paid a trailing twelve-month dividend of HKD 0.03 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 1349.HK go public?
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (1349.HK) completed its initial public offering in 2002.